Last updated on April 2018

Study of EDO-S101 A First-in-Class Alkylating HDACi Fusion Molecule in Relapsed/Refractory Hematologic Malignancies


Brief description of study

This study evaluates the efficacy, safety and pharmacokinetics of EDO-S101 in patients with relapsed/refractory hematologic malignancies. All patients will receive EDO-S101.

Detailed Study Description

EDO-S101 is a new chemical entity, a first-in-class fusion molecule of an alkylator, bendamustine and a histone-deacetylase inhibitor (HDACi), vorinostat. It is anticipated that EDO-S101 may have activity in various hematological malignancies and solid tumors. This phase 1 study will enroll patients with various hematological malignancies.

The study consists of 2 stages:

  • Stage 1: Dose Escalation to determine Maximum Tolerated Dose (MTD) at the optimal infusion time and the pharmacokinetic (PK) profiles; is expected to enroll between 21 and 48 patients
  • Stage 2: Expansion in four Cohorts, in which approximately 12 patients will be enrolled per cohort, for a total of 48 patients.

In Stage 1, EDO-S101 doses will be escalated following the standard 3+3 design. The decision to escalate to the next dose level will occur after all cohort patients have completed 3 weeks (21 days) of observation and have been evaluated for safety and toxicity.The starting dose is a 1 hour infusion of 20 mg/m2, and the maximum dose level is 150 mg/m2. Reduced infusion times of 45 minutes and 30 minutes will also be assessed once the maximum tolerated dose at a 1-hour infusion is determined.

In Stage 2, four cohorts of patients (with relapsed/refractory multiple myeloma or Waldenstrm Macroglobulinemia; relapsed/refractory Hodgkin's lymphoma; relapsed/refractory peripheral T-cell lymphoma, or relapsed/refractory non-Hodgkin's lymphoma [except chronic lymphocytic and cutaneous T-cell lymphoma] who have been treated or are refractory to bendamustine); and relapsed/refractory peripheral T-cell lymphoma (PTCL) and T-cell Prolymphocytic leukemia (T-PLL) will be enrolled and treated at the recommended Phase 2 dose (RP2D) based on results of Stage 1. Treatment will occur every 21 days. Patients in each stage of the study are expected to receive a median of four 3-week Cycles of therapy, and the maximum number of treatment Cycles allowed is 6.

Clinical Study Identifier: NCT02576496

Contact Investigators or Research Sites near you

Start Over

Leif Bergsagel, MD

Mayo Clinic
Phoenix, AZ United States
  Connect »

Han W. Tun, MD

Mayo Clinic Cancer Center
Jacksonville, FL United States
  Connect »

Hartmut Goldschmidt, MD

University Hospital of Heidelberg - medical department V
Heidelberg, Germany
  Connect »

Luigi Zinzani, MD

Institute of Hematology "L. A. Ser gnoli", University of Bologna
Bologna, Italy
  Connect »

Antonio Pinto, MD

National Cancer Institute, Fondazione 'G. Pascale'
Naples, Italy
  Connect »

Christoph Driessen, MD

Kantonsspital St.Gallen
St.Gallen, Switzerland
  Connect »

Owen A O'Connor, MD,PhD

Columbia University Medical Center
New York, NY United States
  Connect »

Von Treskow, MD

University Hospital of Cologne - Department I of Internal Medicine
Köln, Germany
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.